Pancreatic Ductal Adenocarcinoma Pipeline Analysis, 2024 Updates | Latest FDA, EMA, and PMDA Approvals | Elicio Therapeutics, Cend Therapeutics, Silenseed Ltd, Amplia Therapeutics Limited, Bristol-Myers Squibb, Revolution Medicines, Inc., Taiho Pharma, Ge

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Pancreatic Ductal Adenocarcinoma pipeline constitutes 80+ key companies continuously working towards developing 80+ Pancreatic Ductal Adenocarcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Pancreatic Ductal Adenocarcinoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pancreatic Ductal Adenocarcinoma Market.

The Pancreatic Ductal Adenocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report: https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Pancreatic Ductal Adenocarcinoma treatment therapies with a considerable amount of success over the years.
• Pancreatic Ductal Adenocarcinoma companies working in the treatment market are Deciphera Pharmaceuticals, Revolution Medicines, Syntrix Biosystems, Amplia Therapeutics, ZielBio, Cend Therapeutics Inc, Cardiff Oncology, Eucure Biopharma, Jiangsu Alphamab Biopharmaceuticals, and others, are developing therapies for the Pancreatic Ductal Adenocarcinoma treatment
• Emerging Pancreatic Ductal Adenocarcinoma therapies in the different phases of clinical trials are- DCC-3116, RMC-6236, SX-682, AMP 945, ZB131, CEND-1, Onvansertib, YH003, KN046, and others are expected to have a significant impact on the Pancreatic Ductal Adenocarcinoma market in the coming years.
• In January 2022, Jiangsu Alphamab Biopharmaceuticals initiated a multicenter, randomized, double-blind Phase III study in first-line Advanced Pancreatic Ductal Adenocarcinoma subjects (ENREACH-PDAC-01) to compare the efficacy and safety of KN046 combined with Gemcitabine and Nab-Paclitaxel versus placebo combined with Gemcitabine and Nab-Paclitaxel.
• In July 2022, Cend Therapeutics, Inc. reported that data from the Phase 1b study of CEND-1, Cend's lead investigational drug, in combination with gemcitabine and nab-paclitaxel for the treatment of first-line, metastatic pancreatic ductal adenocarcinoma ("mPDAC") were published in The Lancet Gastroenterology and Hepatology.
• In July 2022, I-Mab reported that a Phase 1 international multi-center clinical trial (IMCT) for patients with solid tumors, such as gastric cancer, gastroesophageal junction carcinoma, esophageal adenocarcinoma, and pancreatic ductal carcinoma, has treated the first patient in China with TJ-CD4B (also known as ABL111), a novel Claudin 18.2 x 4-1BB bispecific antibody.
• In June 2022, The mRNA-based personalized neoantigen-specific immunotherapy (iNeST) autogene cevumeran (also known as BNT122, RO7198457) in combination with the anti-PD-L1 immune checkpoint inhibitor atezolizumab and chemotherapy in patients with resected pancreatic ductal adenocarcinoma (PDAC) was recently evaluated for safety and tolerability in a first-in-human Phase 1 study. It was confirmed that the method of tumor profiling for tailored vaccine creation and on-demand production of iNeST in a clinically appropriate period is feasible. The early findings revealed a good safety profile and heartening hints of clinical activity.
• In June 2022, In order to advance Motixafortide through a randomized Phase 2b clinical trial in pancreatic ductal adenocarcinoma, or PDAC, BioLineRx Ltd. stated that the firm had entered into a collaboration agreement with GenFleet Therapeutics, an immuno-oncology-focused biopharmaceutical firm with headquarters in China.
• In May 2022, Elicio Therapeutics announced that it had signed a clinical supply agreement with Regeneron to test the safety and effectiveness of using Regeneron's Libtayo® (cemiplimab), a fully human monoclonal antibody that targets the immune checkpoint receptor PD-1 on T cells, in combination with Elicio's lead asset, ELI-002, an investigational KRAS-targeted cancer vaccine, in patients with KRAS-driven tumors. Stage III and Stage IV non-small cell lung cancer (NSCLC), Stage IV colorectal cancer (CRC), and unresectable, locally progressed, or oligometastatic pancreatic ductal adenocarcinoma (PDAC) are among the KRAS-driven malignancies that will be examined with the combo therapy.
• In May 2022, At the American Society of Clinical Oncology (ASCO) Annual Meeting, which was held from June 4-7, 2022 in Chicago, OSE Immunotherapeutics SA, its clinical partners GERCOR, ARCAGY-GINECO, and the FoRT Foundation (Fondazione Ricerca Traslazionale), announced four poster presentations featuring the neoepitope combination Tedopi® in various cancer indications. The first poster was titled "A randomized non-comparative phase II study of maintenance OSE2101 vaccine alone or in combination with nivolumab (nivo), or FOLFIRI after induction with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): first interim results of the TEDOPAM GERCOR D17-01 PRODIGE 63 STUDY".
• In May 2022, The Phase 2 phase of Purple Biotech Ltd.'s ongoing investigation of CM24, a first-in-class monoclonal antibody with the potential to treat various malignancies, has begun. The objective of the open-label, multicenter Phase 2 research is to assess the safety and tolerability of CM24 in combination with the PD-1 inhibitor Opdivo® (nivolumab) and chemotherapy in patients with metastatic pancreatic adenocarcinoma (PDAC). Evaluating preliminary efficacy in PDAC treated as a second line is the study's main goal.
• In March 2022, The company's flagship asset, mitazalimab, is being tested in the ongoing OPTIMIZE-1 clinical Phase Ib/II trial for the treatment of first-line metastatic pancreatic cancer. Phase Ib of the research has been successfully finished with the safety assessment of the second dose-escalation cohort (900 g/kg of mitazalimab in conjunction with mFOLFIRINOX) being completed. The 900 g/kg mitazalimab dose had been deemed safe by the Data Review Committee, and it was suggested that the Phase II study should proceed with the current dosing level. Phase II enrollment has started and is still going on at locations in Europe. Patients with metastatic pancreatic ductal adenocarcinoma are being evaluated for the safety and effectiveness of mitazalimab in OPTIMIZE-1, an open-label, multi-center Phase Ib/II research.
• In November 2021, The IND application for the phase III registration trial (KN046-303) of the PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel/gemcitabine for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC) has been authorized by the Center for Drug Evaluation (CDE) of the NMPA.

Pancreatic Ductal Adenocarcinoma Overview
Due to delayed diagnosis and a poor prognosis, pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive, fatal cancer. More than 90% of cases of pancreatic cancer are caused by this form of tumor, which is the most common type and develops in the exocrine compartment.

Get a Free Sample PDF Report to know more about Pancreatic Ductal Adenocarcinoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Pancreatic Ductal Adenocarcinoma Drugs Under Different Phases of Clinical Development Include:
• DCC-3116: Deciphera Pharmaceuticals
• RMC-6236: Revolution Medicines
• SX-682: Syntrix Biosystems
• AMP 945: Amplia Therapeutics
• ZB131: ZielBio
• CEND-1: Cend Therapeutics Inc
• Onvansertib: Cardiff Oncology
• YH003: Eucure Biopharma
• KN046: Jiangsu Alphamab Biopharmaceuticals

Pancreatic Ductal Adenocarcinoma Route of Administration
Pancreatic Ductal Adenocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous

Pancreatic Ductal Adenocarcinoma Molecule Type
Pancreatic Ductal Adenocarcinoma Products have been categorized under various Molecule types, such as
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics Assessment
• Pancreatic Ductal Adenocarcinoma Assessment by Product Type
• Pancreatic Ductal Adenocarcinoma By Stage and Product Type
• Pancreatic Ductal Adenocarcinoma Assessment by Route of Administration
• Pancreatic Ductal Adenocarcinoma By Stage and Route of Administration
• Pancreatic Ductal Adenocarcinoma Assessment by Molecule Type
• Pancreatic Ductal Adenocarcinoma by Stage and Molecule Type

DelveInsight's Pancreatic Ductal Adenocarcinoma Report covers around 80+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Pancreatic Ductal Adenocarcinoma product details are provided in the report. Download the Pancreatic Ductal Adenocarcinoma pipeline report to learn more about the emerging Pancreatic Ductal Adenocarcinoma therapies at:
https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Pancreatic Ductal Adenocarcinoma Therapeutics Market include:
Key companies developing therapies for Pancreatic Ductal Adenocarcinoma are - Elicio Therapeutics, Cend Therapeutics, Silenseed Ltd, Amplia Therapeutics Limited, Bristol-Myers Squibb, Revolution Medicines, Inc., Taiho Pharmaceutical, Genmab, Deciphera Pharmaceuticals LLC, NGM Biopharmaceuticals, Multitude Therapeutics, Seagen Inc., Alligator Bioscience, Cardiff Oncology, Novartis, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Cantargia AB, Nelum Corp, GC Cell Corporation, OSE Immunotherapeutics, Eucure (Beijing) Biopharma Co., Ltd, Panbela Therapeutics, Inc., Onconic Therapeutics Inc., Tarveda Therapeutics, I-Mab Biopharma Co. Ltd., Incyte Corporation, ZielBio, Inc., DrugCendR Inc., Bayer, TriSalus Life Sciences, Jacobio Pharma, BioLineRx Ltd., Purple Biotech Ltd., Biomea Fusion, Inc., Phanes Therapeutics, Qualigen Therapeutics, and others.

Pancreatic Ductal Adenocarcinoma Pipeline Analysis:
The Pancreatic Ductal Adenocarcinoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Pancreatic Ductal Adenocarcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Ductal Adenocarcinoma Treatment.
• Pancreatic Ductal Adenocarcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Pancreatic Ductal Adenocarcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pancreatic Ductal Adenocarcinoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Pancreatic Ductal Adenocarcinoma drugs and therapies-
https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pancreatic Ductal Adenocarcinoma Pipeline Market Drivers
• Increasing pervasiveness of the disease, increasing demand of targeted therapy are some of the important factors that are fueling the Pancreatic Ductal Adenocarcinoma Market.

Pancreatic Ductal Adenocarcinoma Pipeline Market Barriers
• However, lack of early diagnostic markers, complicated and multifactorial nature of disease, diverse genetics and rapid metastasis and other factors are creating obstacles in the Pancreatic Ductal Adenocarcinoma Market growth.

Scope of Pancreatic Ductal Adenocarcinoma Pipeline Drug Insight
• Coverage: Global
• Key Pancreatic Ductal Adenocarcinoma Companies: Deciphera Pharmaceuticals, Revolution Medicines, Syntrix Biosystems, Amplia Therapeutics, ZielBio, Cend Therapeutics Inc, Cardiff Oncology, Eucure Biopharma, Jiangsu Alphamab Biopharmaceuticals, and others
• Key Pancreatic Ductal Adenocarcinoma Therapies: DCC-3116, RMC-6236, SX-682, AMP 945, ZB131, CEND-1, Onvansertib, YH003, KN046, and others
• Pancreatic Ductal Adenocarcinoma Therapeutic Assessment: Pancreatic Ductal Adenocarcinoma current marketed and Pancreatic Ductal Adenocarcinoma emerging therapies
• Pancreatic Ductal Adenocarcinoma Market Dynamics: Pancreatic Ductal Adenocarcinoma market drivers and Pancreatic Ductal Adenocarcinoma market barriers

Request for Sample PDF Report for Pancreatic Ductal Adenocarcinoma Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Pancreatic Ductal Adenocarcinoma Report Introduction
2. Pancreatic Ductal Adenocarcinoma Executive Summary
3. Pancreatic Ductal Adenocarcinoma Overview
4. Pancreatic Ductal Adenocarcinoma- Analytical Perspective In-depth Commercial Assessment
5. Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics
6. Pancreatic Ductal Adenocarcinoma Late Stage Products (Phase II/III)
7. Pancreatic Ductal Adenocarcinoma Mid Stage Products (Phase II)
8. Pancreatic Ductal Adenocarcinoma Early Stage Products (Phase I)
9. Pancreatic Ductal Adenocarcinoma Preclinical Stage Products
10. Pancreatic Ductal Adenocarcinoma Therapeutics Assessment
11. Pancreatic Ductal Adenocarcinoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Pancreatic Ductal Adenocarcinoma Key Companies
14. Pancreatic Ductal Adenocarcinoma Key Products
15. Pancreatic Ductal Adenocarcinoma Unmet Needs
16 . Pancreatic Ductal Adenocarcinoma Market Drivers and Barriers
17. Pancreatic Ductal Adenocarcinoma Future Perspectives and Conclusion
18. Pancreatic Ductal Adenocarcinoma Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Pancreatic Ductal Adenocarcinoma Market https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Pancreatic Ductal Adenocarcinoma Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom).

Latest Reports:
B-cell Non-hodgkin Lymphoma Market https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-market
DelveInsight's "B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-Cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Systemic Sclerosis Market
https://www.delveinsight.com/report-store/systemic-sclerosis-market
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Systemic Sclerosis. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Systemic Sclerosis segmented by gender-specific, age-specific, and type-specific cases.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.